The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 29, 2026 | Innovative Cellular Therapeutics Holdings Ltd | 10% Owner | Other(J) | 76K | — | $0 |
| Jun 15, 2026 | Innovative Cellular Therapeutics Holdings Ltd | 10% Owner | Other(J) | 67K | — | $0 |
| Jun 10, 2026 | Nabel Elizabeth G | Director | Grant(A) | 9K | — | $0 |
| Jun 10, 2026 | Ramachandra Sumant | Director | Grant(A) | 9K | — | $0 |
| Jun 10, 2026 | Klausner Richard | Director | Grant(A) | 9K | — | $0 |
| Jun 10, 2026 | Bachleda Mark | Director | Grant(A) | 9K | — | $0 |
| Jun 10, 2026 | Shook David | Chief Medical Officer | Sell(S) | 2K | $12.64 | $25K |
| Jun 10, 2026 | Rieflin William JL | Director | Grant(A) | 9K | — | $0 |
| Jun 10, 2026 | Friedman Cathy | Director | Grant(A) | 9K | — | $0 |
| Jun 10, 2026 | Brawley Otis W | Director | Grant(A) | 9K | — | $0 |
| May 11, 2026 | Seely Lynn | President and CEO, Director | Sell(S) | 388 | $18.91 | $7K |
| May 11, 2026 | Lee Gary K. | Chief Scientific Officer | Sell(S) | 130 | $18.92 | $2K |
| May 11, 2026 | Hill Stephen J. | Chief Operating Officer | Sell(S) | 89 | $18.92 | $2K |
| May 11, 2026 | Bulis Veronica Sanchez | VP, Corporate Controller | Sell(S) | 217 | $18.91 | $4K |
| Mar 9, 2026 | Shah Smital | Chief Fin. and Bus. Officer | Grant(A) | 140K | — | $0 |
| Mar 6, 2026 | Berns Paul L | 10% Owner | Buy(P) | 488K | $25.61 | $12.5M |
| Mar 6, 2026 | ARCH Venture Partners IX Overage, L.P. | 10% Owner | Buy(P) | 488K | $25.61 | $12.5M |
| Feb 11, 2026 | Seely Lynn | President and CEO, Director | Sell(S) | 7K | $23.39 | $174K |
| Feb 11, 2026 | Hill Stephen J. | Chief Operating Officer | Sell(S) | 1K | $23.39 | $29K |
| Feb 11, 2026 | Lee Gary K. | Chief Scientific Officer | Sell(S) | 2K | $23.39 | $39K |
| Feb 10, 2026 | Seely Lynn | President and CEO, Director | Sell(S) | 438 | $23.12 | $10K |
| Feb 10, 2026 | Seely Lynn | President and CEO, Director | Grant(A) | 155K | — | $0 |
| Feb 10, 2026 | Meltz Mark A | General Counsel | Grant(A) | 50K | — | $0 |
| Feb 10, 2026 | Hill Stephen J. | Chief Operating Officer | Sell(S) | 109 | $23.12 | $3K |
| Feb 10, 2026 | Hill Stephen J. | Chief Operating Officer | Grant(A) | 65K | — | $0 |
| Feb 10, 2026 | Lee Gary K. | Chief Scientific Officer | Sell(S) | 147 | $23.12 | $3K |
| Feb 10, 2026 | Lee Gary K. | Chief Scientific Officer | Grant(A) | 50K | — | $0 |
| Feb 10, 2026 | Shook David | Chief Medical Officer | Grant(A) | 50K | — | $0 |
| Feb 10, 2026 | Bulis Veronica Sanchez | VP, Corporate Controller | Sell(S) | 254 | $23.12 | $6K |
| Feb 10, 2026 | Bulis Veronica Sanchez | VP, Corporate Controller | Grant(A) | 9K | — | $0 |
| Feb 9, 2026 | Seely Lynn | President and CEO, Director | Grant(A) | 20K | — | $0 |
| Feb 9, 2026 | Hill Stephen J. | Chief Operating Officer | Grant(A) | 4K | — | $0 |
| Feb 9, 2026 | Lee Gary K. | Chief Scientific Officer | Grant(A) | 4K | — | $0 |
| Dec 30, 2025 | Bulis Veronica Sanchez | VP, Corporate Controller | Sell(S) | 936 | $32.32 | $30K |
| Dec 24, 2025 | Bulis Veronica Sanchez | VP, Corporate Controller | Sell(S) | 1K | $38.67 | $44K |
| Nov 10, 2025 | Seely Lynn | President and CEO, Director | Sell(S) | 412 | $16.11 | $7K |
| Nov 10, 2025 | Hill Stephen J. | Chief Operating Officer | Sell(S) | 95 | $16.12 | $2K |
| Nov 10, 2025 | Lee Gary K. | Chief Scientific Officer | Sell(S) | 138 | $16.16 | $2K |
| Nov 10, 2025 | Bulis Veronica Sanchez | VP, Corporate Controller | Sell(S) | 239 | $16.10 | $4K |
| Oct 27, 2025 | Seely Lynn | President and CEO, Director | Grant(A) | 175K | — | $0 |
| Oct 27, 2025 | Hill Stephen J. | Chief Operating Officer | Grant(A) | 75K | — | $0 |
| Oct 27, 2025 | Lee Gary K. | Chief Scientific Officer | Grant(A) | 68K | — | $0 |
| Aug 21, 2025 | Lee Gary K. | Chief Scientific Officer | Sell(S) | 1K | $10.54 | $15K |
| Aug 21, 2025 | Newton Charles W. | Chief Financial Officer | Sell(S) | 1K | $10.54 | $15K |
| Aug 21, 2025 | Hill Stephen J. | Chief Operating Officer | Sell(S) | 1K | $10.54 | $11K |
| Aug 21, 2025 | Seely Lynn | President and CEO, Director | Sell(S) | 7K | $10.54 | $76K |
| Aug 20, 2025 | Lee Gary K. | Chief Scientific Officer | Grant(A) | 8K | — | $0 |
| Aug 20, 2025 | Newton Charles W. | Chief Financial Officer | Grant(A) | 8K | — | $0 |
| Aug 20, 2025 | Hill Stephen J. | Chief Operating Officer | Grant(A) | 8K | — | $0 |
| Aug 20, 2025 | Seely Lynn | President and CEO, Director | Grant(A) | 40K | — | $0 |
| Aug 12, 2025 | Newton Charles W. | Chief Financial Officer | Sell(S) | 136 | $10.34 | $1K |
| Aug 12, 2025 | Lee Gary K. | Chief Scientific Officer | Sell(S) | 136 | $10.34 | $1K |
| Aug 12, 2025 | Hill Stephen J. | Chief Operating Officer | Sell(S) | 94 | $10.34 | $972 |
| Aug 12, 2025 | Seely Lynn | President and CEO, Director | Sell(S) | 406 | $10.34 | $4K |
| Aug 11, 2025 | Newton Charles W. | Chief Financial Officer | Sell(S) | 131 | $10.53 | $1K |
| Aug 11, 2025 | Lee Gary K. | Chief Scientific Officer | Sell(S) | 131 | $10.53 | $1K |
| Aug 11, 2025 | Hill Stephen J. | Chief Operating Officer | Sell(S) | 91 | $10.53 | $958 |
| Aug 11, 2025 | Seely Lynn | President and CEO, Director | Sell(S) | 391 | $10.53 | $4K |
| Jun 9, 2025 | Shook David | Chief Medical Officer | Grant(A) | 22K | — | $0 |
| Jun 9, 2025 | Shook David | Chief Medical Officer | Grant(A) | 44K | — | $0 |
| Jun 9, 2025 | Meltz Mark A | General Counsel | Grant(A) | 100K | — | $0 |
| Jun 9, 2025 | Bachleda Mark | Director | Grant(A) | 13K | — | $0 |
| May 15, 2025 | Ramachandra Sumant | Director | Grant(A) | 130K | — | $0 |
| May 15, 2025 | Nabel Elizabeth G | Director | Grant(A) | 130K | — | $0 |
| May 15, 2025 | Brawley Otis W | Director | Grant(A) | 130K | — | $0 |
| May 15, 2025 | Friedman Cathy | Director | Grant(A) | 130K | — | $0 |
| May 15, 2025 | Rieflin William JL | Director | Grant(A) | 130K | — | $0 |
| May 15, 2025 | Klausner Richard | Director | Grant(A) | 130K | — | $0 |
| Mar 31, 2025 | Brawley Otis W | Director | Buy(P) | 36K | $0.56 | $20K |
| Mar 21, 2025 | Ramachandra Sumant | Director | Buy(P) | 200K | $0.58 | $116K |
| Mar 17, 2025 | Newton Charles W. | Chief Financial Officer | Buy(P) | 200K | $0.56 | $112K |
| Mar 14, 2025 | Seely Lynn | President and CEO, Director | Buy(P) | 175K | $0.61 | $107K |
| Mar 14, 2025 | Klausner Richard | Director | Buy(P) | 158K | $0.60 | $95K |
| Feb 10, 2025 | Lee Gary K. | Chief Scientific Officer | Grant(A) | 113K | — | $0 |
| Feb 10, 2025 | Lee Gary K. | Chief Scientific Officer | Grant(A) | 56K | — | $0 |
| Feb 10, 2025 | Lee Gary K. | Chief Scientific Officer | Grant(A) | 450K | — | $0 |
| Feb 10, 2025 | Newton Charles W. | Chief Financial Officer | Grant(A) | 113K | — | $0 |
| Feb 10, 2025 | Newton Charles W. | Chief Financial Officer | Grant(A) | 450K | — | $0 |
| Feb 10, 2025 | Newton Charles W. | Chief Financial Officer | Grant(A) | 56K | — | $0 |
| Feb 10, 2025 | Hill Stephen J. | Chief Operating Officer | Grant(A) | 113K | — | $0 |
| Feb 10, 2025 | Hill Stephen J. | Chief Operating Officer | Grant(A) | 56K | — | $0 |
| Feb 10, 2025 | Hill Stephen J. | Chief Operating Officer | Grant(A) | 450K | — | $0 |
| Feb 10, 2025 | Seely Lynn | President and CEO, Director | Grant(A) | 338K | — | $0 |
| Feb 10, 2025 | Seely Lynn | President and CEO, Director | Grant(A) | 1.4M | — | $0 |
| Feb 10, 2025 | Seely Lynn | President and CEO, Director | Grant(A) | 169K | — | $0 |
| Feb 10, 2025 | Lang Matthew | Chief Business Officer | Grant(A) | 113K | — | $0 |
| Feb 10, 2025 | Lang Matthew | Chief Business Officer | Grant(A) | 450K | — | $0 |
| Feb 10, 2025 | Lang Matthew | Chief Business Officer | Grant(A) | 56K | — | $0 |
| Oct 31, 2024 | Ramachandra Sumant | Director | Grant(A) | 260K | — | $0 |
| Jun 14, 2024 | Friedman Cathy | Director | Grant(A) | 130K | — | $0 |
| Jun 14, 2024 | Brawley Otis W | Director | Grant(A) | 130K | — | $0 |
| Jun 14, 2024 | Nabel Elizabeth G | Director | Grant(A) | 130K | — | $0 |
| Jun 14, 2024 | Rieflin William JL | Director | Grant(A) | 130K | — | $0 |
| Jun 14, 2024 | Klausner Richard | Director | Grant(A) | 130K | — | $0 |
| Jun 14, 2024 | Bishop Hans Edgar | Director | Grant(A) | 130K | — | $0 |
| Jun 14, 2024 | Nelsen Robert | Director, 10% Owner | Grant(A) | 130K | — | $0 |
| Feb 9, 2024 | Seely Lynn | President and CEO, Director | Grant(A) | 200K | — | $0 |
| Feb 9, 2024 | Newton Charles W. | Chief Financial Officer | Grant(A) | 40K | — | $0 |
| Feb 9, 2024 | Newton Charles W. | Chief Financial Officer | Grant(A) | 400K | — | $0 |
| Feb 9, 2024 | Lee Gary K. | Chief Scientific Officer | Grant(A) | 40K | — | $0 |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Coverage: Form 4 filings indexed 2021-03-29 → 2026-07-11. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).